Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were ...
Tag: statin
Rosuvastatin may reduce risk of all-cause mortality and major adverse cardiovascular events compared with atorvastatin
1. In this multi-database retrospective cohort study, rosuvastatin was found to be associated with slightly decreased risk of all-cause mortality ...
Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy
1. In a cohort of individuals with invasive ductal carcinoma (IDC) that underwent breast-conserving surgery (BCS) and adjuvant breast radiotherapy, ...
Statins may improve tolerability of antidepressant therapy
1. In a large population-based cohort study, combination therapy of antidepressant therapy with a statin was associated with fewer antidepressant ...
Statin use for primary and secondary prevention is influenced by social determinants of health
1. In this cross-sectional study, rates of statin use for primary prevention were lower among non-Hispanic Black men and non-Mexican ...
Bempedoic acid reduces the risk of major adverse cardiovascular events
1. In this randomized controlled trial, bempedoic acid significantly reduced low-density lipoprotein (LDL) cholesterol levels in patients with increased cardiovascular ...
C-reactive protein may have superior prognostic value compared to low-density lipoprotein cholesterol for patients on statin therapy
1. High-sensitivity C-reactive protein increased the risk of all-cause mortality by two- to three-fold among all three randomized trials. 2. ...
Treat-to-target approach non-inferior to high-dose statin therapy in patients with coronary artery disease
1. Patients who received statin therapy using a treat-to-target approach (targeting LDL-cholesterol of 50-70mg/dL) did not have worse cardiovascular outcomes ...
#VisualAbstract: Vitamin D supplementation is not preventative for statin-associated muscle symptoms or statin discontinuation
1. A randomized controlled trial found that pretreatment with supplemental vitamin D did not reduce the risk of statin-associated muscle ...
![Ivabradine ineffective in stable coronary artery disease [SIGNIFY trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/09/800px-RCA_atherosclerosis-350x250.jpg)
Olpasiran significantly reduces lipoprotein(a) levels in patients with cardiovascular disease
1. Olpasiran significantly and substantially reduced lipoprotein(a) concentration in patients with atherosclerotic cardiovascular disease compared to placebo. 2. Olpasiran reduced ...